Parasomnias
Movements or behaviors associated with sleep, sleep stages, or partial arousals from sleep that may impair sleep maintenance. Parasomnias are generally divided into four groups: arousal disorders, sleep-wake transition disorders, parasomnias of REM sleep, and nonspecific parasomnias. (From Thorpy, Sleep Disorders Medicine, 1994, p191)
Subtype terms (7)
More specific conditions that are subtypes of Parasomnias in the MeSH hierarchy.
- Nocturnal Myoclonus Syndrome
- Nocturnal Paroxysmal Dystonia
- REM Sleep Parasomnias
- Restless Legs Syndrome
47 drugs (36 approved, 11 experimental)
- Sleep Arousal Disorders
- Sleep Bruxism
11 drugs (8 approved, 3 experimental)
- Sleep-Wake Transition Disorders
6 drugs (5 approved, 1 experimental)
Organizations
Organization Involved with Phase 4 Indications (54)
- Takeda
- Forest Laboratories
- Gilead Sciences
- AstraZeneca
- Merck
- Pfizer
- Wyeth
- Kuhnil Pharmaceutical Co., Ltd.
- Shaanxi Buchang Pharmaceutical Co., Ltd
- SRI International
- Sunovion
- Teva
- Boehringer Ingelheim
- TTY Biopharm
- National Institute on Drug Abuse (NIDA)
- Region Syddanmark
- University of Arizona
- University of Pittsburgh
- Chang Gung University
- Cleveland Sleep Research Center
- Clinique Beau Soleil
- Harvard University
- Inje University
- Johns Hopkins University
- Mental Health Services in the Capital Region, Denmark
- Midtown Medical Center, Tampa, FL
- Shanghai University of Traditional Chinese Medicine
- University of Southern Denmark
- Yonsei University
- Mayo Clinic
- +24 more
Organization Involved with Phase 3 Indications (34)
- XenoPort, Inc.
- Cephalon
- Bioprojet
- GlaxoSmithKline
- Neurim Pharmaceuticals Ltd.
- Targeted Medical Pharma
- Nobel Pharmaceuticals
- National Cancer Institute (NCI)
- Herlev Hospital
- Cancer and Leukemia Group B (CALGB)
- University of London
- Hoosier Cancer Research Network
- International Breast Cancer Study Group
- Loma Linda University
- Meander Medical Center
- University of Brasilia
- Kurume University
- Southeast Renal Research Institute
- University of Cincinnati
- University of Copenhagen
- Free University of Amsterdam
- Koege and Roskilde Hospital
- Psychiatric Research Unit, Region Zealand
- National Taiwan University
- Pennsylvania State University
- Neurocenter of Southern Switzerland, Lugano
- Universidade Federal do Parana
- Dutch Kidney Foundation
- Pharma Nord
- Lundbeck
- +4 more
Organization Involved with Phase 2 Indications (31)
- Sanofi
- Sanofi-Synthelabo
- Kyowa Hakko Kirin
- The EMMES Corporation
- National Institutes of Health (NIH)
- British Columbia Cancer Agency
- National Center for Complementary and Integrative Health (NCCIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Case Western Reserve University
- Melbourne Health
- Northern California Institute of Research and Education
- Rhode Island Hospital
- University of Michigan
- Wake Forest University
- University of Zurich
- University of Colorado, Denver
- Department of Defense
- Clinilabs
- Kyowa Kirin
- University of Texas at Houston
- Sleep Disorders Center of Atlanta
- University of New South Wales
- University of Colorado
- The Florey Institute of Neuroscience and Mental Health
- Office of Dietary Supplements (ODS)
- Autism Treatment Network
- Health Resources and Services Administration (HRSA)
- Damon Runyon Cancer Research Foundation
- American Academy of Sleep Medicine
- +1 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (13)
- Jazz Pharmaceuticals
- National Institute of Mental Health (NIMH)
- National Institute of Nursing Research (NINR)
- United States Army
- Baylor University
- University of Washington
- Oregon Health and Science University
- Stanford University
- Thomas Jefferson University
- University of Nebraska
- Institute of Liver and Biliary Sciences, India
- University of Colorado, Boulder
- Huntington's Disease Society of America